DocG DocG | AI-Powered Clinical Summaries
Sign In

Stay Current with Medical Literature

AI-powered clinical summaries delivered to your inbox 3 times per week. Evidence-based insights in 300 words, designed for busy physicians.

Sign Up

See What You Get

Subscribers receive email summaries and access to our interactive AI-powered article rankings.

Email Summary Example

Benefit greatest in higher-risk COVID-19 outpatients
Among outpatients in the Omicron period, nirmatrelvir plus ritonavir was linked to fewer hospitalizations and deaths, with the largest absolute benefit in moderate- and high-risk patients.
*Systematic review and meta-analysis of cohort studies; Level 2a (OCEBM).

Citation

Ebell M, Kurotschka P. Effectiveness of Nirmatrelvir/Ritonavir for Outpatients in the Era of Omicron, Vaccination, and Previous Infection: A Meta-analysis. Journal of General Internal Medicine. 2026. doi:10.1007/s11606-026-10494-4

Background

Earlier trials of nirmatrelvir plus ritonavir (Paxlovid) occurred before widespread vaccination and prior infection. This review asked whether it still helps prevent hospitalization and death among contemporary outpatients.

Patients

Adults and adolescents (12 years or older) with COVID-19 managed as outpatients during the Omicron period (data collection started no earlier than December 2021). Excluded: initially hospitalized patients; studies without adjusted analyses; non–peer-reviewed reports; and special populations (such as pregnancy or specific diseases like cancer or transplant).

Intervention

Nirmatrelvir plus ritonavir.

Control

No antiviral treatment.

Outcome

30-day hospitalization (all-cause and COVID-19-related) and 30-day death (all-cause and COVID-19-related); also a combined outcome of hospitalization or death.

Follow-up Period

30 days.

Results

Outcome (30-day) Pooled adjusted relative risk (95% confidence interval)
All-cause hospitalization 0.54 (0.43 to 0.68)
COVID-19 hospitalization (primary) 0.45 (0.36 to 0.56)
All-cause death 0.30 (0.23 to 0.39)
Estimated number needed to treat to prevent one COVID-19 hospitalization (using external baseline-risk groups): low risk 1148; moderate risk 84; high risk 20.

Limitations

All included studies were observational, so unmeasured differences between treated and untreated groups may still explain part of the benefit. Results varied across studies, and definitions of “immunocompromised” and outcomes differed. For low-risk patients, the absolute benefit is very small despite favorable relative risk.

Funding

No project-specific funding reported.

Clinical Application

Use nirmatrelvir plus ritonavir mainly for moderate- and high-risk outpatients; expect minimal absolute benefit in low-risk patients and prioritize shared decision-making and drug–drug interaction review.

Top Journal Rankings - August 2026

1686 abstracts scored across 7 criteria. Click any article to expand criterion scores.
1. 8.5
Assessment of adverse effects attributed to statin therapy in product labels: a meta-analysis of double-blind randomised controlled trials.
Overall: This large, rigorous analysis is highly relevant to primary care and may substantially improve statin risk counseling by showing that most labeled adverse effects lack support from blinded randomized evidence.
View 6 Criterion Scores
Primary-Care Relevance & Applicability 9.5
Statin prescribing and counseling about adverse effects are common, directly applicable decisions in US primary care.
Validity, Bias Control & Precision 9.5
This individual-participant-data meta-analysis included 123,940 participants from large, long-term, double-blind randomized trials and used confidence intervals and false-discovery-rate control.
Patient-Oriented Outcomes 8.5
It assessed numerous potential adverse effects important to patients, including cognitive, mood, sleep, neurologic, and edema outcomes, although some significant findings were laboratory abnormalities.
Magnitude of Net Benefit 6.0
The study provides substantial reassurance that most labeled adverse effects are not causally supported, while identified absolute excesses were generally small; it did not directly measure improvements in treatment uptake or clinical outcomes.
Implementability & Practicality 9.0
The findings can be incorporated readily into routine statin counseling without new tests, equipment, monitoring systems, or complex workflow changes.
Practice-Changing Potential 8.5
The strong evidence could materially change counseling and attribution of symptoms and supports revision of product labels, although label changes require action beyond individual practices.
2. 8.3
Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism.
Overall: This large randomized head-to-head trial found a clinically meaningful reduction in bleeding with apixaban using an intervention that is immediately applicable to outpatient VTE treatment, although recurrent thrombotic outcomes were not presented.
View 6 Criterion Scores
Primary-Care Relevance & Applicability 9.0
Acute venous thromboembolism is common, and choosing between apixaban and rivaroxaban is directly relevant to US outpatient clinicians managing anticoagulation.
Validity, Bias Control & Precision 8.5
This was a large international randomized trial with blinded endpoint assessment, balanced allocation, little apparent loss after randomization, and a precise primary estimate, although treatment was open-label.
Patient-Oriented Outcomes 8.0
Clinically relevant bleeding is important to patients, but the primary composite combined major and clinically relevant nonmajor bleeding without reporting their separate effects.
Magnitude of Net Benefit 7.0
Apixaban reduced clinically relevant bleeding from 7.1% to 3.3%, an absolute reduction of 3.8 percentage points, while other serious adverse events were similar; however, comparative recurrent thrombosis results were not reported.
Implementability & Practicality 9.0
Both drugs are commonly used oral anticoagulants with familiar dosing regimens, so clinicians can readily apply the finding without new equipment, training, or monitoring systems.
Practice-Changing Potential 8.5
The direct randomized comparison provides compelling evidence favoring apixaban when bleeding risk informs selection between these commonly used treatments, though absent comparative efficacy results limit certainty about overall superiority.
3. 8.3
High-Dose vs Standard-Dose Influenza Vaccines in Older Adults: A Meta-Analysis.
Overall: High-Dose vs Standard-Dose Influenza Vaccines in Older Adults: A Meta-Analysis provides strong, precise, and directly applicable evidence that high-dose vaccination reduces hospitalization outcomes in older adults, though absolute benefits, adverse effects, and mortality improvement are not demonstrated.
View 6 Criterion Scores
Primary-Care Relevance & Applicability 10.0
Influenza vaccination of adults aged 65 years or older is a common US primary-care decision, and the comparison involves vaccines used in routine outpatient care.
Validity, Bias Control & Precision 9.0
This meta-analysis included 8 randomized trials and 605,098 participants, used independent review and risk-of-bias assessment, and reported consistent sensitivity analyses with relatively precise estimates.
Patient-Oriented Outcomes 9.0
The principal outcomes were hospitalizations and all-cause mortality, which are directly important to patients, although no mortality benefit was found.
Magnitude of Net Benefit 6.0
High-dose vaccination reduced several hospitalization outcomes, including influenza hospitalization, but absolute risk reductions and adverse effects were not reported, and mortality was unchanged.
Implementability & Practicality 9.0
Substituting one influenza vaccine formulation for another fits existing vaccination workflows and requires no additional diagnostic testing or follow-up described in the abstract.
Practice-Changing Potential 7.0
The large randomized evidence synthesis can strengthen vaccine recommendations and formulation choice, although the abstract notes that superior protection had already been demonstrated.
4. 8.2
Pharmacological blood-pressure lowering for the prevention of cardiovascular disease and death across the full spectrum of chronic kidney disease severity: an individual-participant data meta-analysis.
Overall: A large, precise randomized-trial meta-analysis supports blood-pressure lowering to prevent major cardiovascular events throughout CKD, but absent absolute effects and harms limit conclusions about net benefit.
View 6 Criterion Scores
Primary-Care Relevance & Applicability 9.0
Hypertension and CKD are common in US primary care, and blood-pressure treatment is a routine outpatient decision.
Validity, Bias Control & Precision 9.0
This prespecified individual-participant meta-analysis included 285,124 participants from 46 eligible RCTs, used time-to-event methods, and reported a precise cardiovascular estimate.
Patient-Oriented Outcomes 9.0
The primary composite comprised fatal or nonfatal stroke, ischemic heart disease, heart-failure hospitalization, and cardiovascular death.
Magnitude of Net Benefit 6.5
A 5 mm Hg systolic reduction was associated with a modest but clinically meaningful relative cardiovascular risk reduction in CKD, but absolute benefits and treatment harms were not reported.
Implementability & Practicality 8.5
Blood-pressure lowering uses familiar medications and monitoring pathways that are readily available in routine US outpatient practice.
Practice-Changing Potential 7.0
The findings strengthen treatment across CKD stages and blood-pressure thresholds, although they largely reinforce established blood-pressure management rather than define a new regimen.
5. 8.1
Therapy for Atrial Fibrillation in Patients with Drug-Eluting Stents.
Overall: Therapy for Atrial Fibrillation in Patients with Drug-Eluting Stents provides strong randomized evidence that a simpler NOAC-only regimen substantially reduces clinically important events, mainly bleeding, although applicability beyond the South Korean trial population and detailed ischemic safety remain less certain.
View 6 Criterion Scores
Primary-Care Relevance & Applicability 7.5
Atrial fibrillation and long-term antithrombotic therapy are common outpatient issues, although post-stent treatment decisions are often shared with cardiology and the trial was conducted in South Korea.
Validity, Bias Control & Precision 8.0
This was a multicenter randomized trial with 960 participants, a prespecified noninferiority margin, and reasonably precise estimates; its open-label design and 12-month follow-up are limitations.
Patient-Oriented Outcomes 8.0
The primary composite included death, myocardial infarction, stent thrombosis, stroke, systemic embolism, and clinically important bleeding, although separate ischemic outcome results were not reported.
Magnitude of Net Benefit 8.5
Monotherapy reduced net adverse events by 7.6 percentage points and bleeding by approximately 8 percentage points, representing a large clinically meaningful benefit with less treatment burden.
Implementability & Practicality 9.5
Stopping clopidogrel while continuing an established NOAC is straightforward, reduces medication burden, and requires no new equipment, testing, or specialized workflow.
Practice-Changing Potential 7.0
The findings strongly reinforce NOAC monotherapy after the first post-stent year, but the abstract notes that guidelines already recommend this approach.
6. 8.1
Infant Outcomes, Risk Factors, and Diagnostic Yield After a Brief Resolved Unexplained Event: A Systematic Review and Meta-Analysis.
Overall: This robust meta-analysis supports a practical, risk-informed approach to BRUE and may meaningfully reduce low-yield testing while preserving attention to serious diagnoses.
View 6 Criterion Scores
Primary-Care Relevance & Applicability 7.5
BRUE is relevant to US pediatric and family medicine, particularly for initial assessment and follow-up, although acute evaluation often occurs in emergency or hospital settings.
Validity, Bias Control & Precision 8.5
This systematic review included 24 studies and 6603 infants, used verified extraction, random-effects meta-analysis, and GRADE; however, the included designs were largely observational and mortality estimates remained imprecise.
Patient-Oriented Outcomes 9.0
Serious underlying diagnoses and 3-month mortality are directly important to patients, while diagnostic yield also informs avoidance of unnecessary testing.
Magnitude of Net Benefit 7.0
The extremely low yields of routine tests support reducing low-value investigations and false-positive findings, although the review did not directly measure outcomes from implementing a targeted strategy.
Implementability & Practicality 8.0
Focusing testing on multiple events and prematurity while avoiding blanket investigations is practical and could reduce cost and burden, though the abstract does not provide a complete clinical algorithm.
Practice-Changing Potential 8.5
The findings challenge routine testing and the use of age 60 days or younger as an independent risk factor, providing a strong basis for guideline revision and more selective evaluation.
7. 7.9
Stroke and Bleeding Risks With Non-Vitamin K Oral Anticoagulants in Nonvalvular Atrial Fibrillation.
Overall: This large, directly applicable US cohort supports apixaban as having the most favorable comparative benefit-harm profile in younger adults with atrial fibrillation, but residual confounding and absent absolute event rates temper confidence.
View 6 Criterion Scores
Primary-Care Relevance & Applicability 9.0
Choosing an oral anticoagulant for nonvalvular atrial fibrillation is a common US outpatient decision, and the FDA Sentinel population is directly relevant to US practice.
Validity, Bias Control & Precision 7.5
This was a very large claims-based cohort using inverse probability weighting and reporting confidence intervals, but its nonrandomized design remains vulnerable to residual confounding.
Patient-Oriented Outcomes 9.0
The study evaluated clinically important outcomes, including thromboembolic stroke, intracranial hemorrhage, gastrointestinal bleeding, and major extracranial bleeding.
Magnitude of Net Benefit 6.0
Apixaban was associated with substantially less major and gastrointestinal bleeding than rivaroxaban without a significant stroke difference, but absolute event rates and absolute benefits were not reported.
Implementability & Practicality 9.0
The findings can be implemented through selection among commonly prescribed oral anticoagulants without adding tests, visits, procedures, or specialized infrastructure.
Practice-Changing Potential 7.0
The results may strengthen preference for apixaban in adults younger than 65 years, although the observational design and need for further investigation limit stand-alone practice-changing certainty.
8. 7.9
Asundexian for Secondary Stroke Prevention.
Overall: This large, rigorous trial found a modest but clinically meaningful reduction in recurrent ischemic stroke without a demonstrated increase in major bleeding, making the findings likely to influence secondary prevention practice.
View 6 Criterion Scores
Primary-Care Relevance & Applicability 8.0
Secondary prevention after noncardioembolic stroke or high-risk TIA is highly relevant to longitudinal US primary care, although treatment initiation may involve hospital-based or specialist care.
Validity, Bias Control & Precision 9.0
This was a large phase 3 double-blind randomized placebo-controlled trial with 12,327 participants, balanced groups, and a precise primary estimate, although follow-up duration and attrition are not reported in the abstract.
Patient-Oriented Outcomes 9.5
The primary outcome was recurrent ischemic stroke, with major cardiovascular events, major bleeding, serious adverse events, and death from cardiovascular causes also assessed.
Magnitude of Net Benefit 6.0
Asundexian reduced ischemic stroke from 8.4% to 6.2%, an absolute reduction of 2.2%, while major bleeding and overall serious adverse events were similar between groups.
Implementability & Practicality 7.0
Once-daily oral therapy is operationally straightforward, but it adds another medication to antiplatelet therapy, and the abstract does not address cost, access, monitoring, or treatment duration.
Practice-Changing Potential 8.0
A positive, large phase 3 trial showing fewer recurrent strokes without significantly more major bleeding could alter secondary-prevention regimens, subject to regulatory approval and guideline adoption.
9. 7.9
Discontinuation of Beta-Blocker Therapy after Myocardial Infarction.
Overall: This randomized trial provides clinically meaningful evidence that stable patients without heart failure or substantial systolic dysfunction may discontinue beta-blockers after the first post-infarction year without worse major clinical outcomes.
View 6 Criterion Scores
Primary-Care Relevance & Applicability 7.5
Long-term beta-blocker management after myocardial infarction is a common outpatient decision, although the trial was conducted entirely in South Korea and included relatively few women.
Validity, Bias Control & Precision 8.0
This was a multicenter randomized trial with prespecified noninferiority methods and 3.1 years of median follow-up; limitations include its open-label design, relatively few events, and a noninferiority margin allowing a hazard ratio up to 1.4.
Patient-Oriented Outcomes 9.0
The primary composite consisted entirely of important clinical outcomes: all-cause death, recurrent myocardial infarction, and hospitalization for heart failure.
Magnitude of Net Benefit 6.0
Discontinuation was noninferior, with 4-year event estimates of 7.2% versus 9.0% and similar serious adverse events, but superiority and improvements in symptoms, quality of life, or medication burden were not demonstrated.
Implementability & Practicality 9.0
Stopping a long-term medication is straightforward and requires no specialized equipment, although clinicians must confirm stable post-infarction status, ejection fraction of at least 40%, and absence of heart failure.
Practice-Changing Potential 8.0
The findings directly support deprescribing beta-blockers after at least one year in a defined post-infarction population, potentially changing a common long-term prescribing practice.
10. 7.8
Mobile Chat Messaging for Smoking Relapse Prevention: A Randomized Clinical Trial.
Overall: A well-conducted randomized trial found a large, clinically meaningful improvement in validated smoking abstinence, although its Hong Kong cessation-service setting and live-counselor requirements modestly limit direct US implementation.
View 6 Criterion Scores
Primary-Care Relevance & Applicability 7.0
Smoking relapse is common and directly relevant to US primary care, although the trial involved two Hong Kong smoking-cessation services rather than routine US practices.
Validity, Bias Control & Precision 8.5
This randomized trial used a contact control, intention-to-treat analysis, biochemical validation, 98% retention, and confidence intervals, although masking was not reported.
Patient-Oriented Outcomes 8.5
Sustained smoking abstinence and relapse are meaningful outcomes, and the primary outcome was biochemically validated rather than based solely on self-report.
Magnitude of Net Benefit 8.5
Validated abstinence improved by 10.4 percentage points, corresponding to an approximate NNT of 10, while relapse fell by 11.9 points; harms were not reported and live counseling adds burden.
Implementability & Practicality 7.0
Messaging and chatbot support are scalable, but three months of access to a live counselor requires staffing and workflow resources not available in every practice.
Practice-Changing Potential 7.5
The intervention could strengthen relapse-prevention care for a common problem, but adoption in US primary care may require confirmation of transferability and a workable counseling model.
Score Guide: 9-10 Exceptional 7-8 Strong 5-6 Moderate 3-4 Weak 1-2 Poor
Showing top 10 of 1686

How It Works

1

Sign Up with Google

Create your account in seconds using your Google account. No passwords to remember.

2

Receive Email Summaries

Get AI-curated clinical summaries delivered to your inbox three times per week (Monday, Wednesday, Friday).

3

Find the Best New Articles

Our interactive article rankings allow you to find the best articles, tailored to you.

Ready to Stay Current?

Sign Up